芯動聯科(688582.SH):公司產品可應用於人形機器人,但沒有人形機器人相關的直接研究成果
格隆匯8月14日丨有投資者向芯動聯科(688582.SH)提問,“作為世界技術領先的傳感器企業,公司有沒有和特斯拉接觸過。公司闡述經營狀況逐步良好,那麼今後發展方向國內外更側重哪裏呢。目前公司佔比最大的產品是在什麼行業應用的呢。公司在人形機器人方面有沒有研究成果?”
公司回覆稱,公司相關客户信息請參見定期公吿。公司目前着重於國內市場。公司主要應用於高可靠,無人系統及高端工業方面的應用。公司產品可應用於人形機器人,但公司產品為慣性傳感器,沒有人形機器人相關的直接研究成果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.